Get Regeneron Pharmaceuticals alerts:Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) – Research analysts at Leerink Partnrs dropped their Q4 2025 EPS estimates for shares of Regeneron Pharmaceuticals in a report issued on Tuesday, September 30th. The consensus estimate for Regeneron Pharmaceuticals’ current full-year earnings is $35.92 per share. Regeneron Pharmaceuticals Trading Up 6.7%Shares of REGN opened at $599.94 on Wednesday. Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last posted its quarterly earnings results on Friday, August 1st. Featured ArticlesReceive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.